Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up
You may also be interested in...
CoreValve Expands Percutaneous Aortic Valve Trial In Europe
CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end
CoreValve Expands Percutaneous Aortic Valve Trial In Europe
CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end
Percutaneous Aortic Valve IDE Approval Rests On Clearer Criteria – Edwards
Edwards Lifesciences will work with FDA on crafting an acceptable definition for "high-risk patients" to meet an investigational device exemption approval goal of early 2005 for its percutaneous aortic valve, the firm said in a Dec. 3 investor conference